Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading drug discovery firm leveraging artificial intelligence. The partnership combines GATC's proprietary Multiomics Advanced Technology (MAT) AI platform with Lisata's expertise in drug development to reduce risks and improve efficiency in bringing new therapies to market.
Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants John Menditto - Vice President of Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer Kristen Buck - Executive Vice President of R&D and Chief Medical Officer James Nisco - Senior Vice President of Finance and Treasury and Chief Accounting Officer Conference Call Participants Sara Nik - H.C. Wainwright Peter Enderlin - MAZ Partners Steve Brozak - WBB Securities, LLC Kemp Dolliver - Brookline Capital Markets Operator Welcome to the Lisata Therapeutics' Full Year 2024 Financial Results and Business Update Conference Call.
Lisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progress
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a statement accompanying its full-year 2024 financial results. The pharmaceutical company highlighted progress in its clinical pipeline, including encouraging preliminary data from a Phase 2b pancreatic cancer trial.
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compay's pancreatic cancer trials. The company recently announced preliminary results from its Phase 2ASCEND trial at the ASCO Gastrointestinal conference.
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The iLSTA trial is being conducted at St John of God Subiaco Hospital in Western Australia, involving 30 patients divided into three treatment cohorts.
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is evaluating the efficacy of Lisata's novel therapy certepetide in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), an aggressive form of pancreatic cancer.
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership
Lisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead investigational drug candidate, certepetide. The company announced the completion of patient enrollment in the Phase 1b/2a CENDIFOX trial, evaluating its iRGD cyclic peptide, certepetide, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
Lisata Therapeutics completes patient enrollment for CENDIFOX trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX trial evaluating the safety and efficacy of Lisata's investigational drug certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon and appendiceal cancers. Certepetide is a cyclic peptide designed to enhance the delivery of anti-cancer drugs by activating a unique pathway that helps them target and penetrate solid tumors more effectively.
Lisata Therapeutics and Kuva Labs to collaborate on cancer imaging solution
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2 Holdings. The clinical-stage pharmaceutical firm said the agreement will give Kuva access to Lisata's iRGD cyclic peptide, certepetide, as a targeting and delivery agent for their NanoMark platform to create a new class of advanced magnetic resonance (MR) imaging agents for the detection of solid tumor cancers.
Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough Awards
Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company said it was recognized for its unique approach to addressing the unmet medical needs of patients with advanced solid tumors, particularly through its proprietary CendR Platform technology which enhances the delivery and efficacy of anti-cancer treatments by targeting the tumor microenvironment.
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and its third quarter financial performance. Mazzo highlighted advancements in Lisata's pancreatic cancer program, specifically the ASCEND trial, which is expected to yield important data soon.
Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO & Director James Nisco - SVP, Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - EVP, R&D & Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Pete Enderlin - MAZ Partners Will Hidell - Brookline Capital Markets Operator Welcome to the Lisata Therapeutics' Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, November 12, 2024.
